Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-04-24

Clinical Trial Update: Phase 2b Study of MBS2320 in Participants With Methotrexate-Refractory RA [Phase 2]

View source ↗

Summary

Phase 2b study of MBS2320 in methotrexate-refractory rheumatoid arthritis has completed, with results posted in April 2025.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • MBS2320

Snippet

Sponsor: Modern Biosciences Ltd | Conditions: Rheumatoid Arthritis | Phase 2 | Status: COMPLETED | Results posted: 2025-04-24